<p>Ensign Peak Advisors Inc 在最近向證券交易委員會提交的 13F 表格中表示，在第二季度將其在 Crinetics Pharmaceuticals, Inc.（NASDAQ:CRNX - 免費報告）中的持股減少了 38.7%。該基金在季度內出售了 199,245 股後，持有該公司 315,564 股股票。截至其最近向證券交易委員會提交的文件，Ensign Peak Advisors Inc 持有 Crinetics Pharmaceuticals 的股份佔比為 0.34%，價值 9,076,000 美元。</p>
<p>其他機構投資者和對沖基金也對該公司的持倉進行了調整。德誠資本（Decheng Capital LLC）在第一季度將其在 Crinetics Pharmaceuticals 的持股提高了 6.0%。德誠資本目前持有 177,958 股該公司的股票，價值 5,969,000 美元，此前在上個季度又購買了 10,000 股。Natixis Advisors LLC 在第一季度將其在 Crinetics Pharmaceuticals 的股份增加了 1.8%。Natixis Advisors LLC 目前持有 46,509 股該公司的股票，價值 1,560,000 美元，此前在上個季度又收購了 826 股。Commerce Bank 在第一季度將其在 Crinetics Pharmaceuticals 的持股提高了 53.2%。Commerce Bank 目前持有 6,320 股該公司的股票，價值 212,000 美元，此前在該期間又購買了 2,195 股。PNC Financial Services Group Inc. 在第一季度將其在 Crinetics Pharmaceuticals 的股份提高了 25.4%。PNC Financial Services Group Inc. 目前持有 3,395 股該公司的股票，價值 114,000 美元，此前在上個季度又購買了 688 股。最後，先鋒集團（Vanguard Group Inc.）在第一季度將其在 Crinetics Pharmaceuticals 的持股提高了 2.4%。先鋒集團目前持有 9,311,600 股該公司的股票，價值 312,311,000 美元，此前在該期間又購買了 222,209 股。98.51% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>Crinetics Pharmaceuticals 的內部買賣</h2>
<p>在 Crinetics Pharmaceuticals 的其他消息中，董事 Matthew K. Fust 於 9 月 26 日星期五出售了 16,000 股該公司的股票。股票以平均價格 44.75 美元出售，總價值為 716,000.00 美元。出售完成後，該董事直接持有 22,836 股公司股票，價值約 1,021,911 美元。這代表其持倉減少了 41.20%。該交易在向證券交易委員會的文件中披露，可以通過此鏈接訪問。此外，首席執行官 Richard Scott Struthers 於 9 月 26 日星期五出售了 4,000 股公司的股票。股票以平均價格 45.00 美元出售，總價值為 180,000.00 美元。交易完成後，首席執行官持有 106,000 股公司股票，價值約 4,770,000 美元。這代表其持倉減少了 3.64%。該交易的披露可在 SEC 文件中找到。內部人士在過去九十天內共出售了價值 1,318,350 美元的 30,000 股公司股票。公司內部人士持有 6.00% 的公司股票。</p>
<h2>Crinetics Pharmaceuticals 的價格表現</h2>
<p>Crinetics Pharmaceuticals 的股票在週一開盤價為 42.86 美元。該公司的市值為 40.7 億美元，市盈率為 -9.46，貝塔係數為 0.25。該公司有 50 天的移動平均線為 41.25 美元，200 天的移動平均線為 34.56 美元。Crinetics Pharmaceuticals, Inc. 的一年最低價為 24.10 美元，一年最高價為 60.34 美元。</p>
<p>Crinetics Pharmaceuticals（NASDAQ:CRNX - 獲取免費報告）最近於 11 月 6 日星期四發佈了季度財報。該公司報告季度每股收益為（1.38 美元），低於市場共識預期的（1.27 美元），差額為（0.11 美元）。該公司季度收入為 14 萬美元，而分析師預期為 39 萬美元。在去年同期，該公司每股收益為（0.96 美元）。研究分析師預計 Crinetics Pharmaceuticals, Inc. 今年的每股收益將為 -3.73 美元。</p>
<h2>華爾街分析師預測增長</h2>
<p>一些分析師最近對 CRNX 股票發佈了報告。羅伯特·W·貝爾德（Robert W. Baird）在 9 月 26 日星期五的研究報告中將 Crinetics Pharmaceuticals 的目標價從 58.00 美元上調至 62.00 美元，並給予該股票 “跑贏大盤” 的評級。高盛集團（Goldman Sachs Group）在 9 月 26 日星期五的報告中將 Crinetics Pharmaceuticals 的目標價從 35.00 美元上調至 40.00 美元，並給予該公司 “中性” 評級。奧本海默（Oppenheimer）在 9 月 30 日星期二的研究報告中將 Crinetics Pharmaceuticals 的目標價從 73.00 美元上調至 87.00 美元，並給予該股票 “跑贏大盤” 的評級。公民 Jmp 在 11 月 7 日星期五的研究報告中將 Crinetics Pharmaceuticals 的目標價從 143.00 美元下調至 108.00 美元，並對該股票設定了 “市場跑贏大盤” 的評級。最後，摩根士丹利（Morgan Stanley）在 9 月 29 日星期一的報告中將 Crinetics Pharmaceuticals 的目標價從 65.00 美元上調至 77.00 美元，並給予該股票 “增持” 的評級。共有十一位股票研究分析師對該股票給予了買入評級，兩位給予了持有評級，一位給予了賣出評級。根據 MarketBeat，該公司目前的共識評級為 “適度買入”，平均目標價為 77.55 美元。</p>
<p><strong>查看我們對 Crinetics Pharmaceuticals 的最新分析</strong></p>
<h2>Crinetics Pharmaceuticals 簡介</h2>
<p>（免費報告）</p>
<p>Crinetics Pharmaceuticals, Inc.是一家臨牀階段的製藥公司，專注於稀有內分泌疾病和內分泌相關腫瘤的新型治療藥物的發現、開發和商業化。該公司的主要產品候選藥物是 paltusotine，一種口服選擇性非肽類生長抑素受體 2 型激動劑，目前正在進行治療肢端肥大症的第三階段臨牀試驗；以及針對與神經內分泌腫瘤相關的類癌綜合症的第二階段臨牀試驗。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們認為比 Crinetics Pharmaceuticals 更好的股票</li>
<li>最佳航空航天股票投資</li>
<li>DoorDash 最近的股票下跌意味着 60% 的上漲空間</li>
<li>如何使用 MarketBeat Excel 股息計算器</li>
<li>華爾街目前熱愛 Williams-Sonoma——這就是為什麼該股票可能在 2026 年飆升的原因</li>
<li>3 只股票引領迷因股復興</li>
<li>Meta 贏得 FTC 訴訟，保持 Instagram 增長機器完好無損</li>
</ul>
<p><strong>想知道其他對 CRNX 感興趣的對沖基金持有哪些股票嗎？</strong> 請訪問 HoldingsChannel.com，獲取 Crinetics Pharmaceuticals, Inc.（NASDAQ:CRNX - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JOWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JOWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Crinetics Pharmaceuticals 嗎？</h2>
<p>在考慮投資 Crinetics Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Crinetics Pharmaceuticals 並不在名單上。</p>
<p>雖然 Crinetics Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

CRNX

<p>Ensign Peak Advisors Inc 在第二季度減少了對 Crinetics Pharmaceuticals 的持股，減持幅度為 38.7%，出售了 199,245 股。其他機構投資者也調整了他們的持倉，其中德誠資本（Decheng Capital LLC）、法興顧問（Natixis Advisors LLC）、商業銀行（Commerce Bank）、PNC 金融服務集團（PNC Financial Services Group Inc.）和先鋒集團（Vanguard Group Inc.）的交易尤為顯著。內部人士最近出售了 30,000 股。Crinetics 股票開盤價為 42.86 美元，市值為 40.7 億美元。分析師預測公司將實現增長，羅伯特·W·貝爾德（Robert W. Baird）、高盛（Goldman Sachs）和奧本海默（Oppenheimer）均上調了價格目標</p>

<p>Ensign Peak Advisors Inc lowered its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 38.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities &amp; Exchange Commission. The fund owned 315,564 shares of the company's stock after selling 199,245 shares during the quarter. Ensign Peak Advisors Inc owned 0.34% of Crinetics Pharmaceuticals worth $9,076,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p>
<div class="lb-trans"><p>Ensign Peak Advisors Inc 在最近向證券交易委員會提交的 13F 表格中表示，在第二季度將其在 Crinetics Pharmaceuticals, Inc.（NASDAQ:CRNX - 免費報告）中的持股減少了 38.7%。該基金在季度內出售了 199,245 股後，持有該公司 315,564 股股票。截至其最近向證券交易委員會提交的文件，Ensign Peak Advisors Inc 持有 Crinetics Pharmaceuticals 的股份佔比為 0.34%，價值 9,076,000 美元。</p>
</div><p>Other institutional investors and hedge funds have also made changes to their positions in the company. Decheng Capital LLC raised its position in shares of Crinetics Pharmaceuticals by 6.0% during the 1st quarter. Decheng Capital LLC now owns 177,958 shares of the company's stock valued at $5,969,000 after buying an additional 10,000 shares in the last quarter. Natixis Advisors LLC increased its stake in Crinetics Pharmaceuticals by 1.8% during the first quarter. Natixis Advisors LLC now owns 46,509 shares of the company's stock worth $1,560,000 after acquiring an additional 826 shares during the last quarter. Commerce Bank raised its position in Crinetics Pharmaceuticals by 53.2% during the first quarter. Commerce Bank now owns 6,320 shares of the company's stock valued at $212,000 after purchasing an additional 2,195 shares during the period. PNC Financial Services Group Inc. lifted its stake in shares of Crinetics Pharmaceuticals by 25.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 3,395 shares of the company's stock valued at $114,000 after purchasing an additional 688 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Crinetics Pharmaceuticals by 2.4% in the 1st quarter. Vanguard Group Inc. now owns 9,311,600 shares of the company's stock worth $312,311,000 after purchasing an additional 222,209 shares during the period. 98.51% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他機構投資者和對沖基金也對該公司的持倉進行了調整。德誠資本（Decheng Capital LLC）在第一季度將其在 Crinetics Pharmaceuticals 的持股提高了 6.0%。德誠資本目前持有 177,958 股該公司的股票，價值 5,969,000 美元，此前在上個季度又購買了 10,000 股。Natixis Advisors LLC 在第一季度將其在 Crinetics Pharmaceuticals 的股份增加了 1.8%。Natixis Advisors LLC 目前持有 46,509 股該公司的股票，價值 1,560,000 美元，此前在上個季度又收購了 826 股。Commerce Bank 在第一季度將其在 Crinetics Pharmaceuticals 的持股提高了 53.2%。Commerce Bank 目前持有 6,320 股該公司的股票，價值 212,000 美元，此前在該期間又購買了 2,195 股。PNC Financial Services Group Inc. 在第一季度將其在 Crinetics Pharmaceuticals 的股份提高了 25.4%。PNC Financial Services Group Inc. 目前持有 3,395 股該公司的股票，價值 114,000 美元，此前在上個季度又購買了 688 股。最後，先鋒集團（Vanguard Group Inc.）在第一季度將其在 Crinetics Pharmaceuticals 的持股提高了 2.4%。先鋒集團目前持有 9,311,600 股該公司的股票，價值 312,311,000 美元，此前在該期間又購買了 222,209 股。98.51% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Insider Buying and Selling at Crinetics Pharmaceuticals</h2>
<div class="lb-trans"><h2>Crinetics Pharmaceuticals 的內部買賣</h2>
</div><p>In other Crinetics Pharmaceuticals news, Director Matthew K. Fust sold 16,000 shares of the company's stock in a transaction on Friday, September 26th. The stock was sold at an average price of $44.75, for a total value of $716,000.00. Following the completion of the sale, the director directly owned 22,836 shares in the company, valued at approximately $1,021,911. This represents a 41.20% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, CEO Richard Scott Struthers sold 4,000 shares of the firm's stock in a transaction on Friday, September 26th. The shares were sold at an average price of $45.00, for a total value of $180,000.00. Following the transaction, the chief executive officer owned 106,000 shares in the company, valued at approximately $4,770,000. This represents a 3.64% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 30,000 shares of company stock valued at $1,318,350 in the last ninety days. Corporate insiders own 6.00% of the company's stock.</p>
<div class="lb-trans"><p>在 Crinetics Pharmaceuticals 的其他消息中，董事 Matthew K. Fust 於 9 月 26 日星期五出售了 16,000 股該公司的股票。股票以平均價格 44.75 美元出售，總價值為 716,000.00 美元。出售完成後，該董事直接持有 22,836 股公司股票，價值約 1,021,911 美元。這代表其持倉減少了 41.20%。該交易在向證券交易委員會的文件中披露，可以通過此鏈接訪問。此外，首席執行官 Richard Scott Struthers 於 9 月 26 日星期五出售了 4,000 股公司的股票。股票以平均價格 45.00 美元出售，總價值為 180,000.00 美元。交易完成後，首席執行官持有 106,000 股公司股票，價值約 4,770,000 美元。這代表其持倉減少了 3.64%。該交易的披露可在 SEC 文件中找到。內部人士在過去九十天內共出售了價值 1,318,350 美元的 30,000 股公司股票。公司內部人士持有 6.00% 的公司股票。</p>
</div><h2>Crinetics Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Crinetics Pharmaceuticals 的價格表現</h2>
</div><p>Crinetics Pharmaceuticals stock opened at $42.86 on Monday. The stock has a market cap of $4.07 billion, a price-to-earnings ratio of -9.46 and a beta of 0.25. The firm has a 50-day moving average of $41.25 and a two-hundred day moving average of $34.56. Crinetics Pharmaceuticals, Inc. has a 1 year low of $24.10 and a 1 year high of $60.34.</p>
<div class="lb-trans"><p>Crinetics Pharmaceuticals 的股票在週一開盤價為 42.86 美元。該公司的市值為 40.7 億美元，市盈率為 -9.46，貝塔係數為 0.25。該公司有 50 天的移動平均線為 41.25 美元，200 天的移動平均線為 34.56 美元。Crinetics Pharmaceuticals, Inc. 的一年最低價為 24.10 美元，一年最高價為 60.34 美元。</p>
</div><p>Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.11). The firm had revenue of $0.14 million for the quarter, compared to analysts' expectations of $0.39 million. During the same period in the previous year, the company earned ($0.96) earnings per share. Research analysts expect that Crinetics Pharmaceuticals, Inc. will post -3.73 earnings per share for the current year.</p>
<div class="lb-trans"><p>Crinetics Pharmaceuticals（NASDAQ:CRNX - 獲取免費報告）最近於 11 月 6 日星期四發佈了季度財報。該公司報告季度每股收益為（1.38 美元），低於市場共識預期的（1.27 美元），差額為（0.11 美元）。該公司季度收入為 14 萬美元，而分析師預期為 39 萬美元。在去年同期，該公司每股收益為（0.96 美元）。研究分析師預計 Crinetics Pharmaceuticals, Inc. 今年的每股收益將為 -3.73 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>A number of analysts recently issued reports on CRNX shares. Robert W. Baird raised their price target on Crinetics Pharmaceuticals from $58.00 to $62.00 and gave the stock an &#34;outperform&#34; rating in a research report on Friday, September 26th. The Goldman Sachs Group upped their price target on shares of Crinetics Pharmaceuticals from $35.00 to $40.00 and gave the company a &#34;neutral&#34; rating in a report on Friday, September 26th. Oppenheimer raised their price objective on shares of Crinetics Pharmaceuticals from $73.00 to $87.00 and gave the stock an &#34;outperform&#34; rating in a research note on Tuesday, September 30th. Citizens Jmp cut their target price on Crinetics Pharmaceuticals from $143.00 to $108.00 and set a &#34;market outperform&#34; rating on the stock in a research note on Friday, November 7th. Finally, Morgan Stanley increased their price target on Crinetics Pharmaceuticals from $65.00 to $77.00 and gave the stock an &#34;overweight&#34; rating in a report on Monday, September 29th. Eleven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $77.55.</p>
<div class="lb-trans"><p>一些分析師最近對 CRNX 股票發佈了報告。羅伯特·W·貝爾德（Robert W. Baird）在 9 月 26 日星期五的研究報告中將 Crinetics Pharmaceuticals 的目標價從 58.00 美元上調至 62.00 美元，並給予該股票 “跑贏大盤” 的評級。高盛集團（Goldman Sachs Group）在 9 月 26 日星期五的報告中將 Crinetics Pharmaceuticals 的目標價從 35.00 美元上調至 40.00 美元，並給予該公司 “中性” 評級。奧本海默（Oppenheimer）在 9 月 30 日星期二的研究報告中將 Crinetics Pharmaceuticals 的目標價從 73.00 美元上調至 87.00 美元，並給予該股票 “跑贏大盤” 的評級。公民 Jmp 在 11 月 7 日星期五的研究報告中將 Crinetics Pharmaceuticals 的目標價從 143.00 美元下調至 108.00 美元，並對該股票設定了 “市場跑贏大盤” 的評級。最後，摩根士丹利（Morgan Stanley）在 9 月 29 日星期一的報告中將 Crinetics Pharmaceuticals 的目標價從 65.00 美元上調至 77.00 美元，並給予該股票 “增持” 的評級。共有十一位股票研究分析師對該股票給予了買入評級，兩位給予了持有評級，一位給予了賣出評級。根據 MarketBeat，該公司目前的共識評級為 “適度買入”，平均目標價為 77.55 美元。</p>
</div><p><strong>View Our Latest Analysis on Crinetics Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Crinetics Pharmaceuticals 的最新分析</strong></p>
</div><h2>Crinetics Pharmaceuticals Profile</h2>
<div class="lb-trans"><h2>Crinetics Pharmaceuticals 簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.</p>
<div class="lb-trans"><p>Crinetics Pharmaceuticals, Inc.是一家臨牀階段的製藥公司，專注於稀有內分泌疾病和內分泌相關腫瘤的新型治療藥物的發現、開發和商業化。該公司的主要產品候選藥物是 paltusotine，一種口服選擇性非肽類生長抑素受體 2 型激動劑，目前正在進行治療肢端肥大症的第三階段臨牀試驗；以及針對與神經內分泌腫瘤相關的類癌綜合症的第二階段臨牀試驗。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Crinetics Pharmaceuticals</li>
<li>Best Aerospace Stocks Investing</li>
<li>DoorDash’s Recent Stock Dip Equals 60% Upside</li>
<li>How to Use the MarketBeat Excel Dividend Calculator</li>
<li>Wall Street Loves Williams-Sonoma Right Now—Here’s Why the Stock Could Soar in 2026</li>
<li>3 Tickers Leading a Meme Stock Revival</li>
<li>Meta Wins FTC Fight, Keeps Instagram Growth Machine Intact</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比 Crinetics Pharmaceuticals 更好的股票</li>
<li>最佳航空航天股票投資</li>
<li>DoorDash 最近的股票下跌意味着 60% 的上漲空間</li>
<li>如何使用 MarketBeat Excel 股息計算器</li>
<li>華爾街目前熱愛 Williams-Sonoma——這就是為什麼該股票可能在 2026 年飆升的原因</li>
<li>3 只股票引領迷因股復興</li>
<li>Meta 贏得 FTC 訴訟，保持 Instagram 增長機器完好無損</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding CRNX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他對 CRNX 感興趣的對沖基金持有哪些股票嗎？</strong> 請訪問 HoldingsChannel.com，獲取 Crinetics Pharmaceuticals, Inc.（NASDAQ:CRNX - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JOWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=CRNX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Crinetics Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Crinetics Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Crinetics Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Crinetics Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Crinetics Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Crinetics Pharmaceuticals 並不在名單上。</p>
</div><p>While Crinetics Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Crinetics Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Ensign Peak Advisors Inc 出售了 199,245 股 Crinetics Pharmaceuticals, Inc.（股票代碼：CRNX）